204 related articles for article (PubMed ID: 31219712)
1. Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study.
Acar E; Leblebici A; Ellidokuz BE; Başbınar Y; Kaya GÇ
Br J Radiol; 2019 Sep; 92(1101):20190286. PubMed ID: 31219712
[TBL] [Abstract][Full Text] [Related]
2. Prospective Comparison of PET Imaging with PSMA-Targeted
Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
Acar E; Bekiş R; Polack B
Curr Med Imaging Rev; 2019; 15(6):589-594. PubMed ID: 32008568
[TBL] [Abstract][Full Text] [Related]
5.
Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
[TBL] [Abstract][Full Text] [Related]
6. Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on
Yi Z; Hu S; Lin X; Zou Q; Zou M; Zhang Z; Xu L; Jiang N; Zhang Y
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1523-1534. PubMed ID: 34845536
[TBL] [Abstract][Full Text] [Related]
7.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Donswijk ML; van Leeuwen PJ; Vegt E; Cheung Z; Heijmink SWTPJ; van der Poel HG; Stokkel MPM
BMC Cancer; 2020 Aug; 20(1):723. PubMed ID: 32758168
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
10. Bone metastases in prostate cancer - Gallium-68-labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography - the better tracer?
Agrawal A; Natarajan A; Mithun S; Bakshi G; Joshi A; Murthy V; Menon S; Purandare N; Shah S; Puranik A; Choudhury S; Prakash G; Pal M; Maitre P; Prabhash K; Noronha V; Rangarajan V
Nucl Med Commun; 2022 Dec; 43(12):1225-1232. PubMed ID: 36345767
[TBL] [Abstract][Full Text] [Related]
11. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
13. Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using
Bieth M; Krönke M; Tauber R; Dahlbender M; Retz M; Nekolla SG; Menze B; Maurer T; Eiber M; Schwaiger M
J Nucl Med; 2017 Oct; 58(10):1632-1637. PubMed ID: 28546330
[TBL] [Abstract][Full Text] [Related]
14. Comparison of bone scintigraphy and
Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
16. Factors Predicting Metastatic Disease in
Chiu LW; Lawhn-Heath C; Behr SC; Juarez R; Perez PM; Lobach I; Bucknor MD; Hope TA; Flavell RR
J Nucl Med; 2020 Dec; 61(12):1779-1785. PubMed ID: 32303599
[TBL] [Abstract][Full Text] [Related]
17. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D
Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Ga-68 PSMA positron emission tomography/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients.
Uslu-Beşli L; Sağer S; Akgün E; Asa S; Şahin OE; Demirdağ Ç; Güner E; Khosroshahi BR; Karayel E; Pehlivanoğlu H; Aygün A; Uslu İ; Talat Z; Sönmezoğlu K
Turk J Med Sci; 2019 Feb; 49(1):301-310. PubMed ID: 30761859
[TBL] [Abstract][Full Text] [Related]
20. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
